Michel Detheux insider trades: iTeos Therapeutics (ITOS) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Michel reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 10, 2025 | ITOS | ↓ Sell | 87,765 | $10.02 | $880K | By MG3A | Jun 11, 2025 (1d) |
| Jun 10, 2025 | ITOS | ↓ Sell | 16,800 | $10.03 | $168K | Direct | Jun 11, 2025 (1d) |
| Jun 6, 2025 | ITOS | ↓ Sell | 131,647 | $10.15 | $1.3M | By MG3A | Jun 6, 2025 (0d) |
| Jun 6, 2025 | ITOS | ↓ Sell | 25,200 | $10.15 | $256K | Direct | Jun 6, 2025 (0d) |
| Apr 18, 2022 | ITOS | ↓ Sell | 11,500 | $31.87 | $367K | Direct | Apr 19, 2022 (1d) |
| Mar 22, 2022 | ITOS | ↓ Sell | 18,437 | $34.17 | $630K | Direct | Mar 22, 2022 (0d) |
| Feb 23, 2022 | ITOS | ↓ Sell | 14,500 | $34.34 | $498K | Direct | Feb 24, 2022 (1d) |
| Jan 25, 2022 | ITOS | ↓ Sell | 14,500 | $35.68 | $517K | Direct | Jan 26, 2022 (1d) |
| Dec 22, 2021 | ITOS | ↓ Sell | 44,500 | $44.54 | $2.0M | Direct | Dec 22, 2021 (0d) |
| Nov 23, 2021 | ITOS | ↓ Sell | 14,500 | $36.08 | $523K | Direct | Nov 24, 2021 (1d) |
| Nov 3, 2021 | ITOS | ↓ Sell | 20,557 | $28.55 | $587K | Direct | Nov 3, 2021 (0d) |
| Oct 21, 2021 | ITOS | ↓ Sell | 196 | $28.00 | $5K | Direct | Oct 25, 2021 (4d) |
| Oct 19, 2021 | ITOS | ↓ Sell | 1,836 | $28.01 | $51K | Direct | Oct 19, 2021 (0d) |
| Sep 24, 2021 | ITOS | ↓ Sell | 6,411 | $28.14 | $180K | Direct | Sep 27, 2021 (3d) |
| Sep 2, 2021 | ITOS | ↓ Sell | 20,252 | $28.66 | $581K | Direct | Sep 3, 2021 (1d) |
| Aug 31, 2021 | ITOS | ↓ Sell | 14,663 | $28.13 | $412K | Direct | Aug 31, 2021 (0d) |
| Aug 25, 2021 | ITOS | ↓ Sell | 8,585 | $28.06 | $241K | Direct | Aug 25, 2021 (0d) |
| Jun 14, 2021 | ITOS | ↓ Sell | 29,000 | $28.50 | $827K | Direct | Jun 16, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Michel Detheux's insider trades
Michel Detheux is Chief Executive Officer at iTeos Therapeutics (ITOS). Since Jun 14, 2021, Michel has reported no open-market purchases and 18 sales worth $10.0M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (9 filings), option exercises (5 filings), gifts (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ITOS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.